Portal de Periódicos da CAPES

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

2015; Springer Nature; Volume: 5; Issue: 3 Linguagem: Inglês

10.1038/bcj.2015.19

2044-5385

Estelle Saland, Héléna Boutzen, Rémy Castellano, Laurent Pouyet, Emmanuel Griessinger, Clément Larrue, Fabienne de Toni, Sarah Scotland, Marion David, G. Danet-Desnoyers, François Vergez, Yara Barreira, Yves Collette, Christian Récher, J-E Sarry,

Immune cells in cancer

Abstract Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute myeloid leukemia (AML). Current in vivo models based on the use of patient samples are not easy to establish and manipulate in the laboratory. Our objective was to develop robust xenograft models of human AML using well-characterized cell lines as a more accessible and faster alternative to those incorporating the use of patient-derived AML cells. Five widely used AML cell lines representing various AML subtypes were transplanted and expanded into highly immunodeficient non-obese diabetic/LtSz-severe combined immunodeficiency IL2Rγ c null mice (for example, cell line-derived xenografts). We show here that bone marrow sublethal conditioning with busulfan or irradiation has equal efficiency for the xenotransplantation of AML cell lines. Although higher number of injected AML cells did not change tumor engraftment in bone marrow and spleen, it significantly reduced the overall survival in mice for all tested AML cell lines. On the basis of AML cell characteristics, these models also exhibited a broad range of overall mouse survival, engraftment, tissue infiltration and aggressiveness. Thus, we have established a robust, rapid and straightforward in vivo model based on engraftment behavior of AML cell lines, all vital prerequisites for testing new therapeutic agents in preclinical studies.